$23.33
4.54% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US67080M1036
Symbol
NRIX
Sector
Industry

Nurix Therapeutics Inc Target price 2024 - Analyst rating & recommendation

Nurix Therapeutics Inc Classifications & Recommendation:

Buy
92%
Hold
8%

Nurix Therapeutics Inc Price Target

Target Price $29.38
Price $23.33
Potential
Number of Estimates 13
13 Analysts have issued a price target Nurix Therapeutics Inc 2025 . The average Nurix Therapeutics Inc target price is $29.38. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 13 analysts: 12 Analysts recommend Nurix Therapeutics Inc to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Nurix Therapeutics Inc stock has an average upside potential 2025 of . Most analysts recommend the Nurix Therapeutics Inc stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Nov '23 2024
Estimates
Revenue Million $ 76.99 58.90
99.30% 23.50%
EBITDA Margin -183.67% -296.09%
59.00% 61.20%
Net Margin -221.53% -323.46%
64.16% 46.01%

11 Analysts have issued a sales forecast Nurix Therapeutics Inc 2024 . The average Nurix Therapeutics Inc sales estimate is

$58.9m
Unlock
. This is
5.46% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$80.0m 28.41%
Unlock
, the lowest is
$29.0m 53.45%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $77.0m 99.30%
2024
$58.9m 23.50%
Unlock
2025
$65.0m 10.30%
Unlock
2026
$79.7m 22.70%
Unlock
2027
$111m 38.87%
Unlock
2028
$241m 117.78%
Unlock

2 Analysts have issued an Nurix Therapeutics Inc EBITDA forecast 2024. The average Nurix Therapeutics Inc EBITDA estimate is

$-174m
Unlock
. This is
6.34% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-145m 11.72%
Unlock
, the lowest is
$-204m 24.40%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-141m 18.29%
2024
$-174m 23.32%
Unlock
2025
$-205m 17.64%
Unlock
2026
$-252m 22.88%
Unlock

EBITDA Margin

2023 -183.67% 59.00%
2024
-296.09% 61.20%
Unlock
2025
-315.82% 6.66%
Unlock
2026
-316.27% 0.14%
Unlock

5 Nurix Therapeutics Inc Analysts have issued a net profit forecast 2024. The average Nurix Therapeutics Inc net profit estimate is

$-191m
Unlock
. This is
1.37% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-175m 6.85%
Unlock
, the lowest is
$-212m 12.67%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-171m 28.57%
2024
$-191m 11.70%
Unlock
2025
$-180m 5.75%
Unlock
2026
$-180m 0.22%
Unlock
2027
$-144m 19.71%
Unlock
2028
$-93.5m 35.26%
Unlock

Net Margin

2023 -221.53% 64.16%
2024
-323.46% 46.01%
Unlock
2025
-276.42% 14.54%
Unlock
2026
-225.76% 18.33%
Unlock
2027
-130.53% 42.18%
Unlock
2028
-38.80% 70.28%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Nov '23 2024
Estimates
Earnings Per Share $ -2.65 -2.96
28.57% 11.70%
P/E negative
EV/Sales 18.48

5 Analysts have issued a Nurix Therapeutics Inc forecast for earnings per share. The average Nurix Therapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-2.96
Unlock
. This is
1.37% lower
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-2.72 6.85%
Unlock
, the lowest is
$-3.29 12.67%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-2.65 28.57%
2024
$-2.96 11.70%
Unlock
2025
$-2.79 5.74%
Unlock
2026
$-2.80 0.36%
Unlock
2027
$-2.25 19.64%
Unlock
2028
$-1.45 35.56%
Unlock

P/E ratio

Current -8.00 233.33%
2024
-7.88 1.50%
Unlock
2025
-8.36 6.09%
Unlock
2026
-8.34 0.24%
Unlock
2027
-10.39 24.58%
Unlock
2028
-16.05 54.48%
Unlock

Based on analysts' sales estimates for 2024, the Nurix Therapeutics Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

18.48
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
25.51
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 17.47 634.03%
2024
18.48 5.78%
Unlock
2025
16.75 9.33%
Unlock
2026
13.65 18.50%
Unlock
2027
9.83 27.99%
Unlock
2028
4.51 54.08%
Unlock

P/S ratio

Current 24.12 252.56%
2024
25.51 5.78%
Unlock
2025
23.13 9.33%
Unlock
2026
18.85 18.50%
Unlock
2027
13.58 27.99%
Unlock
2028
6.23 54.08%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today